AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01151852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
Trial: NCT01899898
Drug: Antiepileptic drugs alone
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The anti-epileptic drugs will be continued alone for 3 months following which they will be offered Simplified Modified Atkins Diet
Trial: NCT02030275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: surgery.
Trial: NCT03912220
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug that looks like the experimental drug, nicotinamide riboside tablets.
Trial: NCT02323893
Drug: [18F]F-AraG
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00961779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion
Trial: NCT00669747
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline, 10 ml, i.d. on Days 1 and 15
Trial: NCT02667444
Drug: SB204 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically once daily
Trial: NCT02667444
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically one daily
Trial: NCT00116714
Drug: DMARD
RxNorm normalized name: Disease-modifying antirheumatic drug (DMARD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects were required to initiate, add or change DMARD therapy at study entry.
Trial: NCT00125060
Drug: Simvastatin (20mg versus 80mg/day)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00356109
Drug: Human Insulin Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient specific dose, inhaled, before meals, 6 months
Trial: NCT01025284
Drug: LY2523355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously as a 1-hour infusion
Trial: NCT02511041
Drug: N-Acetylglucosamine (GlcNAc)
RxNorm normalized name: N-Acetylglucosamine
DrugBank: N-Acetylglucosamine (DB00141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylglucosamine (GlcNAc), 2-acetamino-2-deoxy- \<=-Dglucose, or 2- acetylamino)-2- deoxy-D-glucose, is a monosaccharide derivative of glucose. It is classified as dietary supplement in the United States. In general, it is a white and slightly sweet powder that melts at 221 degrees C. The solubility of GlcNAc is 25% in water, and 1% aqueous solutions are colorless and clear. GlcNAc is contraindicated for patients receiving warfarin, chemotherapy or diabetes drugs. As GlcNAc may interfere with blood sugar control during and after surgery, it is contraindicated during the two weeks prior to major surgery.
Trial: NCT02511041
Drug: Uridine
RxNorm normalized name: Uridine
DrugBank: Uridine (DB02745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uridine 5 -monophosphate (UMP) disodium salt is a water soluble colorless crystalline powder which melts at 202oC.
Trial: NCT02320708
Drug: Acetaminophen (ACE) (1000 mg)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Test ACE 500 mg tablets taken orally one time
Trial: NCT02320708
Drug: Commercial Ibuprofen (IBU) (400 mg)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 IBU 200 mg soft-gels taken orally one time
Trial: NCT02320708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo caplets for acetaminophen taken orally one time
Trial: NCT02320708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo soft-gels for ibuprofen taken orally one time
Trial: NCT02320708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo tablets for Test acetaminophen taken orally one time
Trial: NCT00992160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match GW597599 15mg tablet
Trial: NCT02937740
Drug: NATESTO Testosterone Nasal Gel
RxNorm normalized name: testosterone Nasal Gel [Natesto]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be instructed to administer 5.5 mg of testosterone (1 actuation) per nostril of NATESTO Testosterone Nasal Gel once in the morning and once in the evening (at least 6 hours apart), preferably at the same time each day for a total daily dose of 22 mg/day of testosterone. Patients should be instructed to completely depress the pump 1 time in each nostril to receive the total dose.~For three times daily (after Visit 4 \[Day 90\] if symptoms not adequately managed by a BID dose), NATESTO will be administered intranasally once in the morning, once in the afternoon and once in the evening (approximately 6-8 hours apart), preferably at the same time each day for a total daily dose of 33 mg/day of testosterone.
Trial: NCT00459810
Drug: transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol given 0.2mg/day for duration of study.
Trial: NCT04406415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo administered three times daily for up to 5 days
Trial: NCT00033319
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01953705
Drug: Omega 3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fish oil concentrate standardized to long chain n-3 PUFA content
Trial: NCT01953705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02908295
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
Trial: NCT03498313
Drug: Transdermal Estradiol + Placebo
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: .1mg/24hr transdermal estradiol for 14 days starting day 7 after positive urine luteinizing hormone test, plus twice daily placebo pills during the same time frame.
Trial: NCT03498313
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily placebo pills for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
Trial: NCT02061813
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control
Trial: NCT02061813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00626197
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered at a IV dose 500 mg every 2 weeks for up to 6 doses followed by maintenance treatment with azathioprine.
Trial: NCT00626197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered as per schedule in arm description
Trial: NCT00626197
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine was administered at a dose up to 2 mg/kg/day with a maximum dose of 200 mg.
Trial: NCT01667445
Drug: Epimorph
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient to receive 150ug of Epimorph with Spinal anaesthetic. Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
Trial: NCT01667445
Drug: Spinal analgesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient to receive only Spinal anaesthetic (NO EPIMORPH). Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
Trial: NCT00179010
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each
Trial: NCT02913521
Drug: Diclofenac Sodium Gel 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03786484
Drug: PBF-999
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphodiesterase 10 inhibitor (PDE10i)
Trial: NCT00179010
Drug: Adenosine Mono Phosphate (AMP)
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)
Trial: NCT00871624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
Trial: NCT00522548
Drug: Enteric coated mycophenolate sodium
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
Trial: NCT02762643
Drug: Cholecaliferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product is prescribed to all of randomized subjects
Trial: NCT03243825
Drug: chemotherapy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy: (paclitaxel/cisplatinum)
Trial: NCT00615745
Drug: Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
Trial: NCT03055247
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen: 3 mg/kg tid (total daily dose: 9 mg/kg); administered orally from day 1 to day 5 and then from day 14 to the day before the last LP.
Trial: NCT03055247
Drug: Myelostim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myelostim (G-CSF): 5 µg/kg bid (total daily dose 10 µg/kg); administered subcutaneously from day 19 to the day of the last LP.
Trial: NCT04129164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dose matched to VIB4920.
Trial: NCT00002870
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002870
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03950700
Drug: Bupivacaine-epinephrine
RxNorm normalized name: bupivacaine-epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUPIROP® 0.5% ROPSOHN THERAPEUTICS S.A.S
Trial: NCT01131559
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral; 20-70mg/day
Trial: NCT05761418
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: prostaglandin (PG) E2 analog
Trial: NCT02214940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00696943
Drug: ([18F]-ML-10)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]-ML-10 was administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The radiation dose of \[18F\]-ML-10 administered at each session was 300-500 MBq (8.1-13.5 mCi).
Trial: NCT00305227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04361799
Drug: Standard insulin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin therapy according to local clinical practice.
Trial: NCT01781104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo delivered subcutaneously once daily for 14 days.
Trial: NCT02672852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for risankizumab administered by subcutaneous injection
Trial: NCT01923428
Drug: AZD1722
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00206427
Drug: GW572016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib, 500 mg
Trial: NCT01923428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01151306
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20mg once daily (in the evening) for 6 weeks
Trial: NCT01151306
Drug: Lactose tablet
RxNorm normalized name: lactose Oral Tablet
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet taken each evening for 6 weeks
Trial: NCT01704755
Drug: ABT-450/r/ABT-267, ABT-333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet
Trial: NCT00938353
Drug: Placebo solution for nebulisation 2 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose: 4 ml
Trial: NCT00281697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00281697
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received one of the following four standard chemotherapies for metastatic breast cancer.~1. Taxane - Paclitaxel (Taxol) 90 mg/m\^2 IV every week for 3 weeks followed by 1 week of rest; paclitaxel (Taxol) 175 mg/m\^2 IV every 3 weeks, or paclitaxel protein-bound particles (Abraxane) 260 mg/m\^2 IV every 3 weeks; or docetaxel (Taxotere) 75-100 mg/m\^2 IV every 3 weeks.~2. Gemcitabine (Gemzar) 1250 mg/m\^2 IV on Days 1 and 8 of each 3-week cycle.~3. Vinorelbine (Navelbine) 30 mg/m\^2 IV every week of each 3-week cycle.~4. Capecitabine (Xeloda) 1000 mg/m\^2 orally twice daily on Days 1-14 of each 3-week cycle.
Trial: NCT00113295
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02553824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomly assigned to this Arm will have begin with 12 weeks of placebo followed by a 2 week washout. They will then crossover to Qsymia and receive a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
Trial: NCT01779570
Drug: Macrolide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03312842
Drug: CS1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, patients will be assigned to different groups based on their tumor type.
Trial: NCT02666989
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo pills twice a day
Trial: NCT02683239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive sub-cutaneous (SC) injections of matching placebo
Trial: NCT00202020
Drug: Aspirin 100mg/day Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03350490
Drug: Life information rehabilitation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Trial: NCT02104245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02454348
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive norepinephrine (0.05 to 0.5 mcg/kg/min) by continuous infusion with titration by bedside nurse to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
Trial: NCT03165747
Drug: VSL#3
RxNorm normalized name: VSL#3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 strains of live bacteria: Bifidobacterium breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L. paracasei, L. bulgaricus and Streptococcus thermophilus. 900 billion CFU taken orally daily in a single administration.
Trial: NCT03221998
Drug: IV paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 gram paracetamol infusion for moderate pain management
Trial: NCT02005575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03231800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule once daily
Trial: NCT00504673
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003187
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003187
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02137889
Drug: VAY736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAY736 is a human immunoglobulin of the G class (IgG1/k) monoclonal antibody (mAb) designed to specifically bind the BAFF receptor. VAY736 binds primarily to B-cells through its fragment antigen binding (Fab) region, in human whole blood and spleen samples; it does not bind to natural killer (NK) cells, monocytes, dendritic cells, granulocytes, or platelets.
Trial: NCT00768170
Drug: MK0633
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0633 (50 mg) Oral, single dose
Trial: NCT00951015
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: investigational HIV-1 integrase inhibitor
Trial: NCT04644120
Drug: Placebo for ABBV-47D11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion.
Trial: NCT04644120
Drug: Placebo for ABBV-2B04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervenous (IV) Infusion
Trial: NCT02188654
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day of placebo tablets
Trial: NCT00137969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as a sterile liquid for IV administration.
Trial: NCT00137969
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01416389
Drug: LY2523355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously as a one hour infusion
Trial: NCT04406506
Drug: (erythromycin 250 mg IV bolus)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prokinetic (erythromycin 250 mg IV bolus) given to assist the passage of the tube through the pylorus
Trial: NCT02488382
Drug: Lonquek
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given a single fixed dose of Lonquek (Teva LTD), 12-mg subcutaneously.
Trial: NCT02950935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection of placebo solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
Trial: NCT00671996
Drug: Placebo treatment (0.9% NaCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion, 2 micromol/kg, pretreatment 30 minutes before the start of FOLFOX treatment (during the first three FOLFOX treatments)
Trial: NCT03873246
Drug: OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
Trial: NCT00932542
Drug: Eutectic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The eutectic mixture of lidocaine + prilocaine + bupivacaine.
Trial: NCT00932542
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02536820
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actual diabetes treatment in each participant
Trial: NCT03586908
Drug: PHP-201 0.5% ophthalmic solution (topical eye drop)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1, D7: PHP-201 0.5% topical eye drop OU QD(AM), D2\~D6: PHP-201 0.5% topical eye drop OU TID
Trial: NCT04240223
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo